Considerations in the pharmacoeconomics of dry eye.
Dry eye disease diminishes the quality of patients' lives and drives utilization of health care resources. Until recently, all treatments for dry eye have been palliative. A new treatment, cyclosporine A ophthalmic emulsion, addresses the disease's underlying causes. It warrants pharmacoeconomic analysis to determine its place in managed care.